{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:15:45Z","timestamp":1788516945890,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.ijantimicag.2009.07.016","type":"journal-article","created":{"date-parts":[[2009,9,10]],"date-time":"2009-09-10T10:04:44Z","timestamp":1252577084000},"page":"540-543","source":"Crossref","is-referenced-by-count":4,"title":["Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital"],"prefix":"10.1016","volume":"34","author":[{"given":"Pierre","family":"Vaudaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Huggler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis F.","family":"Arhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Moeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2009.07.016_bib1","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI200318535","article-title":"Antimicrobial resistance: the example of Staphylococcus aureus","volume":"111","author":"Lowy","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib2","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1128\/AAC.47.10.3040-3045.2003","article-title":"Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods","volume":"47","author":"Liu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib3","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","article-title":"The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus","volume":"44","author":"Tenover","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","article-title":"Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance","volume":"1","author":"Hiramatsu","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib7","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA; CLSI; 2006."},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib8","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. Document M100-S18. Wayne, PA; CLSI; 2008."},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","article-title":"Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing","volume":"52","author":"Arhin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.diagmicrobio.2008.05.009","article-title":"Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters","volume":"62","author":"Arhin","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib11","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1128\/JCM.42.7.3309-3312.2004","article-title":"A novel multiplex real-time PCR assay for rapid typing of major staphylococcal cassette chromosome mec elements","volume":"42","author":"Francois","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib12","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/504084","article-title":"An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus","volume":"42","author":"Patel","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1086\/507109","article-title":"The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin","volume":"43","author":"Sader","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.00719-07","article-title":"Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding","volume":"52","author":"Jones","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.07.016_bib15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijantimicag.2008.12.010","article-title":"Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy","volume":"33","author":"Tenover","year":"2009","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909003719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909003719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T07:59:00Z","timestamp":1545033540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857909003719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0924857909003719"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.07.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}